PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future.
Virus outbreaks that can develop into dynamic pandemics are a permanent global threat. Besides preventive measures and vaccines, highly effective therapeutics are the backbone of any pandemic response. Evotec's PRROTECT initiative includes the development and delivery of superior novel therapeutics to curb the next viral pandemic. Based on the Company's distinctive set of global capabilities, Evotec is uniquely positioned to develop next-generation therapeutics across all modalities including small molecules, protein degraders, antibodies and immuno-modulators, but excluding vaccines.
PRROTECT will be an open pre-competitive network initiative designed to offer the best protection against future pandemics by including three lines of preparation:
Preparedness against viral threats, i.e. the pre-development of a multimodality pipeline of therapeutic candidates against the most threatening viruses as defined by the
Rapid response technologies to accelerate de novo R&D timelines of highly effective neutralising antibodies using AI & ML platforms (e.g.
Flexible manufacturing network with highly intensified production facilities (J.POD) to provide therapeutic antibodies quickly wherever needed
LET'S CALL EVOTEC | WERNER LANTHALER ON PRROTECT
Dr
Dr
Evotec has already established relationships with academic, Pharma, and public stakeholders in the field of anti-infectives and is currently in discussions with a number of partners on potential opportunities to collaborate on the PRROTECT platform. Furthermore, through its leading expertise in the area, Evotec already has a portfolio of anti-viral therapeutics that is ready to be advanced to other viruses, and the Company expects first clinical data of PRROTECT projects to become available already in 2022.
FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact:
Tel: +1 732.329.2355
(C) 2021 Electronic News Publishing, source